A Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study of the Efficacy and Safety of QL1701 Plus Docetaxel Versus Herceptin® Plus Docetaxel as First Line Therapy in Patients With HER2-positive Metastatic Breast Cancer
NCT05629949
What is this trial?
Generating plain-language summary...
Am I eligible?
Generating eligibility summary...
What's involved?
Summarizing study design...
Where and how to apply
Primary location
Cancer Hospital,Chinese Academy of Medical Sciences
A Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study of the Efficacy and Safety of QL1701 Plus Docetaxel Versus Herceptin® Plus Docetaxel as First Line Therapy in Patients With HER2-positive Metastatic Breast Cancer — TrialFind